Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee's options vest over four years, with continued service required for each vesting installment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (AKBA) granted a newly hired employee options to purchase 8,400 common shares on September 30, 2026, as an employment inducement.
The options have an exercise price of $0.92 per share, equal to the stock's closing price on the grant date. They vest over four years: 25% on the grant's first anniversary and the remaining 75% quarterly thereafter, subject to continued service. Each option has a 10-year term. The grant was made under Nasdaq Listing Rule 5635(c)(4) and is subject to Akebia's inducement award program and stock option agreement.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 8,400 common shares at $0.92 per share create potential dilution if exercised.
Key Figures
- Options granted
- 8,400 shares
- Award to one newly hired employee
- Exercise price
- $0.92 per share
- Equal to the closing price on the grant date
- Vesting period
- 4 years
- Subject to continued service
- Initial vesting
- 25%
- On the first anniversary of the grant date
- Remaining vesting
- 75%
- Quarterly thereafter, subject to continued service
- Option term
- 10 years
- Each stock option
Historical Context
-
Prior inducement award matched the 8,400-share size, $0.92 exercise price and vesting terms.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on September 30, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What employee stock options did Akebia Therapeutics grant on September 30, 2026?
Akebia granted one newly hired employee options to purchase 8,400 common shares at an exercise price of $0.92 per share. The exercise price equals the stock's closing price on the grant date, and the options were an inducement to enter employment.
When do Akebia Therapeutics' September 30, 2026 inducement options vest?
The options vest over four years, with 25% vesting on the grant date's first anniversary and the remaining 75% quarterly thereafter. Each installment requires the employee's continued service with Akebia. Each option has a 10-year term.